AngloGold Ashanti Limited vs Inovio Pharmaceuticals Inc — how do they compare? AngloGold Ashanti Limited trades at $97.75 (market cap $49.28B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: AngloGold Ashanti Limited is far larger — about 627.4× Inovio Pharmaceuticals Inc's market cap, and AngloGold Ashanti Limited pays a 4.64% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AU | INO | |
|---|---|---|
Market Cap | $49.28B | $78.55M |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $2.87 |
52-Week Low | $52.15 | $0.66 |
Enterprise Value | $48.29B | $49.56M |
Dividend Yield | 4.64% | — |
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $97.89, up 0.66% with strong bullish momentum from moving averages. The stock shows robust fundamentals with 32.19% net income margin and 46.5% ROE, supported by rising gold prices and production growth. Recent Q2 2026 earnings beat expectations with $727 million free cash flow, while the company maintains a $2 billion buyback program. Technical indicators show overbought conditions with RSI at 79.27, but institutional interest remains strong with multiple recent position increases.
Outlook remains positive with analyst consensus target of $120.33 (23% upside) and 64% buy ratings. Key catalysts include H2 production growth and shareholder returns, though risks include gold price volatility and operational challenges. The stock trades at reasonable valuations (P/E 13.06, EV/EBITDA 7.58) with improving balance sheet strength (debt-to-asset ratio declining to 15.59%).
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Trailing returns across standard periods
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →